ArticleJournal of clinical microbiology2025
Emergence of terbinafine-resistant
Article in Journal of clinical microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Pooled it
- Pooled it
- Deciphering the genomic landscape ofMicrobial genomics · 2026Article
- Global Spread of Trichophyton indotineae Tracked by Mass Spectrometry Identification Network, 2022-2025.Emerging infectious diseases · 2026Article
- Emerging Global Patterns of Terbinafine Resistance inAntibiotics (Basel, Switzerland) · 2026Review
- In Vitro Antifungal Evaluation, GC-MS Profiling, and Molecular Docking of Eruca sativa Oil, Clove Oil, and Fusarium chlamydosporum Extract Against the Dermatophyte Trichophyton interdigitale.Current microbiology · 2026Article
- Dermatophytosis: An Update on Global Epidemiology.Journal of fungi (Basel, Switzerland) · 2026Review
- Trichophyton indotineae: Rise, Diagnosis, Treatment, and Future Directions.American journal of clinical dermatology · 2026Review
- Fungicidal Activity of the Nitroimidazole-Thiosemicarbazide Derivative 1-[(1-methyl-4-nitroimidazol-2-yl)carbonyl]-4-(3-methylophenyl)thiosemicarbazide AgainstPathogens (Basel, Switzerland) · 2026Article
- Resistance and Recalcitrance in Dermatophytosis: Mechanistic and Clinical Considerations for Keratinized Tissues.Antibiotics (Basel, Switzerland) · 2026Review
- In Vitro Antifungal Activity of Octenidine Against Emerging Dermatophyte Species.Mycopathologia · 2026Article
- Refractory Dermatophytosis Caused by Trichophyton indotineae: A Case Series Highlighting Antifungal Resistance and Management Challenges.Mycopathologia · 2026Article
- Therapeutic Challenges in Case of Trichophyton indotineae Dermatophytosis, Singapore, 2025.Emerging infectious diseases · 2026Article
- The natural history and evolution of dermatophytosis: Host immunity in acute and chronic infection.PLoS pathogens · 2026Article
- The emergence of superficial dermatophytosis due toJournal of clinical microbiology · 2026Article
- Article
- New and Investigational Treatment Options for Dermatomycosis in the Era of Antifungal Resistance.Journal of fungi (Basel, Switzerland) · 2026Review
- Comparison of gradient concentration strip and EUCAST methods for itraconazole and posaconazole MICs inAntimicrobial agents and chemotherapy · 2026Article
- Two cases of sexually transmittedCMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne · 2026Article
- Global Emergence ofInfection and drug resistance · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.